Shubham Pant, MD

Panelists discuss how the MyPathway study and SGNTUC-019 basket trial demonstrated the clinical activity of trastuzumab plus pertuzumab and tucatinib, respectively, in HER2-positive biliary tract cancer (BTC), highlighting key efficacy metrics and safety profiles that inform treatment selection.

Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.

Panelists discuss how the DESTINY-PanTumor 02 trial demonstrated significant efficacy of trastuzumab deruxtecan in HER2-amplified biliary tract cancer (BTC), with promising response rates and durability that support its use as a treatment option for these patients.

Panelists discuss how molecular testing strategies at disease progression are evolving in biliary tract cancer (BTC), with particular focus on HER2-amplification detection methods including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), while noting that HER2 positivity occurs in approximately 5% to 15% of cases.

Panelists discuss how emerging clinical trial data for immunotherapy combinations in first-line advanced biliary tract cancer (BTC) can be effectively translated into real-world treatment decisions, weighing factors such as biomarker status, safety profiles, and treatment sequencing.

Panelists discuss how the practice-changing TOPAZ-1 trial established durvalumab plus gemcitabine/cisplatin as a first-line standard for advanced biliary tract cancer (BTC) while exploring key clinical factors that influence the choice between durvalumab and pembrolizumab-based combinations following the KEYNOTE-966 results.

Panelists discuss how circulating tumor DNA (ctDNA) testing in biliary tract cancer (BTC) presents unique technical and interpretative challenges, including considerations around sensitivity, timing of collection, and clinical validation of results.

Panelists discuss how clinicians are increasingly utilizing both tissue and liquid biopsies with comprehensive DNA/RNA next-generation sequencing (NGS) for biomarker testing in biliary tract cancer (BTC), while noting variations in testing practices across different treatment centers.

Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.

Panelists discuss how physicians typically communicate survival outcomes and prognosis to patients with newly diagnosed advanced biliary tract cancer (BTC), focusing on setting realistic expectations while maintaining hope.

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Shubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Shubham Pant, MD, MBBS, discusses the rationale for the phase 2b HERIZON-BTC-01 trial and shares the results with zanidatamab in previously treated HER2-amplified biliary tract cancer.

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.